In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtech Innovation From An Industrial Perspective: An Interview With GE Healthcare’s John Dineen

Executive Summary

Because the GE brand is so ubiquitous, visible on everything from household appliances to airplane engines, it’s easy to assume a familiarity with GE and, in particular, with what its health care business is all about. But this interview with John Dineen, President and CEO of GE Healthcare and GE Medical Systems Information Technologies Inc. makes clear that GE’s world view is anything but familiar and stands in striking contrast to that of most other medical technology companies.

You may also be interested in...

GE Healthcare CEO Succession: John Flannery In, John Dineen Moves On

The lead GE business development executive John Flannery is taking over the top spot of the firm’s health care business, replacing John Dineen, who is leaving GE after seven years running Healthcare and 28 years at the company.

GE’s Health Care Venture Adventure

GE’s healthymagination has evolved from an initiative focused on marketing, brand, and thought leadership activities into a significant, internally integrated corporate venture function around health care. But whether nimble, out-of-the-box thinking and a VC-like function can thrive inside a massive organization remains to be seen.

Integrated Diagnostics and Personalized Care: An Interview With GE Healthcare

To capitalize on the rapidly growing personalized medicine space, large imaging companies have been diversifying and acquiring in companies with molecular diagnostic product lines and pipelines. Medtech Insight recently spoke with two executives from GE Healthcare: Joe Camaratta, general manager, GE Healthcare's Category Solutions and Marketing Group; and Robert Dann, oncology strategic marketing leader, GE Healthcare's Medical Diagnostics Division, who provided some details on the company's overall strategy for personalized medicine and what these developments might mean for the future of patient care.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts